An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Spruce Biosciences (NASDAQ: SPRB) announced an abstract acceptance for a poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) in Atlanta, GA, scheduled for June 11-14, 2022. The presentation will cover survey results assessing patient perceptions on glucocorticoid treatment for congenital adrenal hyperplasia (CAH). Key details include the session date of June 11, 2022, from 1:00 p.m. to 3:00 p.m. ET, presented by Dr. Chris N. Barnes. The company aims to develop non-steroidal therapies for CAH and is also exploring treatments for polycystic ovary syndrome (PCOS).
Positive
Abstract accepted for presentation at a major medical conference, potentially enhancing visibility among stakeholders.
Focus on unmet needs in rare endocrine disorders, demonstrating a commitment to addressing significant health issues.
Negative
None.
SAN FRANCISCO--(BUSINESS WIRE)--
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, GA. In a recorded presentation, the company will highlight results from a recent survey of individuals living with congenital adrenal hyperplasia (CAH) to assess their perceptions around glucocorticoid treatment regimens and glucocorticoid-associated side effects.
Details are as follows:
Title: (P079) A Survey of Patients Living with CAH Assessing Their Perceptions on Glucocorticoid Regimen and Glucocorticoid-Associated Side Effects
Session Date & Time: 1:00p.m. - 3:00p.m.ET on June 11, 2022 Presenter: Dr. Chris N. Barnes Authors: Dr. Chris N. Barnes, Dr. Rosh Dias, Melodie Feather and Nina Sherpa-Pine
The poster will be on display during the conference in ENDO 2022's virtual poster hall starting on June 11, at 10:00 a.m. ET. Access more information about ENDO 2022 at https://endo2022.endocrine.org.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
What is the significance of the poster presentation at ENDO 2022 for Spruce Biosciences (SPRB)?
The poster presentation at ENDO 2022 allows Spruce Biosciences to share critical survey findings about patient perceptions on glucocorticoid treatments for CAH, enhancing their visibility in the scientific community.
When will the poster presentation by Spruce Biosciences (SPRB) take place?
The poster presentation will occur on June 11, 2022, from 1:00 p.m. to 3:00 p.m. ET during the ENDO 2022 conference.
What disease target is Spruce Biosciences (SPRB) focusing on with their therapies?
Spruce Biosciences is focusing on therapies for congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).
Who is presenting the abstract for Spruce Biosciences (SPRB) at ENDO 2022?
Dr. Chris N. Barnes will present the abstract at ENDO 2022.
